These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 944095)

  • 1. Enhancement of 9-beta-d-arabinofuranosyladenine cytotoxicity to mouse leukemia L1210 in vitro by 2'-deoxycoformycin.
    Cass CE; Au-Yeung TH
    Cancer Res; 1976 Apr; 36(4):1486-91. PubMed ID: 944095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of the antitumor activity of arabinofuranosyladenine of 2'-deoxycoformycin.
    LePage GA; Worth LS; Kimball AP
    Cancer Res; 1976 Apr; 36(4):1481-5. PubMed ID: 946595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effects of 9-beta-D-arabinofuranosyladenine and 2'-deoxycoformycin combinations on intracerebral leukemia.
    Lee SH; Caron N; Kimball AP
    Cancer Res; 1977 Jul; 37(7 Pt 1):1953-5. PubMed ID: 861931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of 2'-deoxycoformycin, 9-beta-D-arabinofuranosyladenine 5'-phosphate, and 1-beta-D-arabinofuranosylcytosine triple combination therapy on intracerebral leukemia 1210.
    Caron N; Lee SH; Kimball AP
    Cancer Res; 1977 Sep; 37(9):3274-9. PubMed ID: 884674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiproliferative effects of 9-beta-D-arabinofuranosyladenine 5'-monophosphate and related compounds in combination with adenosine deaminase inhibitors against mouse leukemia L1210/C2 cells in culture.
    Cass CE; Tan TH; Selner M
    Cancer Res; 1979 May; 39(5):1563-9. PubMed ID: 85484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to 9-beta-D-arabinofuranosyladenine in cultured leukemia L 1210 cells.
    Cass CE; Selner M; Phillips JR
    Cancer Res; 1983 Oct; 43(10):4791-8. PubMed ID: 6603904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation by 2'-deoxycoformycin of the inhibitory effect by 3'-deoxyadenosine (cordycepin) on nuclear RNA synthesis in L1210 cells in vitro.
    Glazer RI; Lott TJ; Peale AL
    Cancer Res; 1978 Aug; 38(8):2233-8. PubMed ID: 307428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the actions of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine on target enzymes from mouse tumor cells.
    White EL; Shaddix SC; Brockman RW; Bennett LL
    Cancer Res; 1982 Jun; 42(6):2260-4. PubMed ID: 7042080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase.
    Brockman RW; Cheng YC; Schabel FM; Montgomery JA
    Cancer Res; 1980 Oct; 40(10):3610-5. PubMed ID: 6254636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two approaches that increase the activity of analogs of adenine nucleosides in animal cells.
    Plunkett W; Cohen SS
    Cancer Res; 1975 Jun; 35(6):1547-54. PubMed ID: 1079475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between incorporation of 9-beta-D-arabinofuranosyladenine in L 1210 DNA and cytotoxicity.
    Kufe DW; Major PP; Munroe D; Egan M; Herrick D
    Cancer Res; 1983 May; 43(5):2000-4. PubMed ID: 6831429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergism between the antiproliferative activities of arabinosyladenine and N6-benzyladenosine.
    Tritsch GL; Nechaev A; Mittelman A
    Cancer Biochem Biophys; 1977; 2(2):87-90. PubMed ID: 567524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy of mouse leukemia L1210 by 1-beta-D-arabinofuranosylcytosine and 6-[(4-nitrobenzyl)thio]-9-beta-D-ribofuranosylpurine.
    Cass CE; Muzik H; Paterson AR
    Cancer Res; 1975 May; 35(5):1187-93. PubMed ID: 1120308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nornyl)adenine on plasma levels and urinary excretion of 9-beta-D-arabinofuranosyladenine in the mouse 1,2,3.
    Suling WJ; Rice LS; Shannon WM
    Cancer Treat Rep; 1978 Mar; 62(3):369-73. PubMed ID: 647695
    [No Abstract]   [Full Text] [Related]  

  • 15. Phospholipid derivatives of nucleoside analogs as prodrugs with enhanced catabolic stability.
    Matsushita T; Ryu EK; Hong CI; MacCoss M
    Cancer Res; 1981 Jul; 41(7):2707-13. PubMed ID: 7248939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mode of action of 9-beta-D-arabinofuranosyladenine on the synthesis of DNA, RNA, and protein in vivo and in vitro.
    Müller WE; Rohde HJ; Beyer R; Maidhof A; Lachmann M; Taschner H; Kahn RK
    Cancer Res; 1975 Aug; 35(8):2160-8. PubMed ID: 1149031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2'-deoxycoformycin (DCF) and 9-beta-D-arabinofuranosyladenine (Ara-A) in the treatment of refractory acute myelocytic leukemia.
    Gray DP; Grever MR; Siaw MF; Coleman MS; Balcerzak SP
    Cancer Treat Rep; 1982 Feb; 66(2):253-7. PubMed ID: 6976833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of diazan on DNA, RNA, and protein synthesis in mouse L1210 leukemia cells sensitive and resistant to the drug].
    Anikin IV; Kukushkina GV; Sokolova IS; Gorbacheva LB
    Izv Akad Nauk SSSR Biol; 1981; (2):291-5. PubMed ID: 7240552
    [No Abstract]   [Full Text] [Related]  

  • 19. Resistance to 9-beta-D-arabinofuranosyladenine in murine tumor cells.
    LePage GA
    Cancer Res; 1978 Aug; 38(8):2314-6. PubMed ID: 580902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proposed mechanism of therapeutic selectivity for 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells.
    Barrueco JR; Jacobsen DM; Chang CH; Brockman RW; Sirotnak FM
    Cancer Res; 1987 Feb; 47(3):700-6. PubMed ID: 3802076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.